![Biotech companies, investors pour billions into mRNA vaccines as research ramps up in cancer and non-communicable diseases](https://cdn.cancerletter.com/media/2023/03/17122912/49-11-mRNA-4x3-1.jpg)
![Biotech companies, investors pour billions into mRNA vaccines as research ramps up in cancer and non-communicable diseases](https://cdn.cancerletter.com/media/2023/03/17122912/49-11-mRNA-4x3-1.jpg)
Cover Story
After the stunning success of mRNA vaccines during the COVID-19 pandemic, researchers and biotech companies are racing to prove the utility of the technology in an array of non-communicable diseases—including cancer, cystic fibrosis, and sickle cell disease.
In Brief
![In Brief](https://cdn.cancerletter.com/media/2019/05/03155624/in-brief-3.jpg)
![In Brief](https://cdn.cancerletter.com/media/2019/05/03155624/in-brief-3.jpg)
Funding Opportunities
Clinical Roundup
![Clinical Roundup](https://cdn.cancerletter.com/media/2019/05/03161627/clinical_roundup.jpg)
![Clinical Roundup](https://cdn.cancerletter.com/media/2019/05/03161627/clinical_roundup.jpg)
Drugs & Targets
Trending Stories
- Edward Sondik, electrical engineer turned public health expert and one-time interim NCI director, dies at 82
- In 1971, Chris Lundy had minute odds of survival. He is now the longest living BMT recipient at the Hutch
- Trump et al. are wrong: Biden Cancer Initiative is not to be confused with the Beau Biden Cancer Moonshot
- NCI’s Virtual Clinical Trials Office fills the staffing shortages at cancer centers
- Elizabeth Comen joins NYU Langone Health’s Perlmutter Cancer Center
- How Beth Carner went from six weeks left to live with stage 4 colon cancer to complete remission